AU Patent

AU2023216654B2 — Processes for the preparation of selective estrogen receptor degraders

Assigned to Eli Lilly and Co · Expires 2025-09-25 · 1y expired

What this patent protects

Patent listed against imlunestrant-tosylate.

Drugs covered by this patent

imlunestrant-tosylate (IMLUNESTRANT TOSYLATE)

Patent Metadata

Patent number: AU2023216654B2
Jurisdiction: AU
Classification: —
Expires: 2025-09-25
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.